CA
NZ
UK
AU
IND
US
…
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-functional and bi-specific antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
TuHURA Biosciences Inc is a Nasdaq-listed biotechnology company; public disclosures are limited but the firm appears focused on development of novel therapeutic candidates. Long-term growth drivers may include clinical and regulatory progress, strategic partnerships, and successful capital raises that could support pipeline advancement, which may benefit investors seeking exposure to early-stage biotech innovation.
Key risks include high probability of clinical or regulatory setbacks, financing and dilution risk, intense competition from larger biopharma, and execution uncertainty inherent to early-stage drug development.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Income before tax | -30.06M | -21.68M | -8.32M | -14.65M | -22.66M |
| Net income | -30.06M | -21.68M | -8.32M | -14.65M | -22.66M |
| Selling general administrative | 7.58M | 3.87M | 4.14M | 2.01M | 2.38M |
| Gross profit | - | -0.12M | -0.06M | -0.06M | -0.06M |
| Reconciled depreciation | 0.07M | 0.12M | 0.18M | 0.37M | 0.38M |
| Ebit | -29.43M | -17.54M | -8.32M | -14.65M | -22.03M |
| Ebitda | -29.36M | -17.43M | -8.27M | -14.59M | -21.97M |
| Depreciation and amortization | 0.07M | 0.12M | 0.06M | 0.06M | 0.06M |
| Operating income | -31.80M | -17.65M | -8.45M | -14.80M | -22.68M |
| Other operating expenses | 31.80M | 17.65M | 8.45M | 14.80M | 22.68M |
| Interest expense | 0.63M | 4.14M | 0.02M | 0.00M | 0.63M |
| Interest income | 0.14M | 0.36M | 0.09M | 0.06M | 0.00M |
| Net interest income | -0.49M | -3.78M | 0.07M | 0.06M | -0.63M |
| Income tax expense | - | - | -0.00M | - | - |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 31.80M | 17.65M | 8.40M | 14.74M | 22.62M |
| Cost of revenue | - | 0.12M | 0.06M | 0.06M | 0.06M |
| Total other income expense net | 1.74M | -4.03M | 0.13M | 0.15M | 0.02M |
| Net income from continuing ops | -30.05M | -21.68M | -29.32M | -9.37M | -7.02M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Total assets | 27.35M | 19.97M | 4.36M | 15.20M | 6.40M |
| Intangible assets | 11.28M | - | - | - | - |
| Other current assets | 1.00M | 6.52M | 0.16M | 0.39M | 0.14M |
| Total liab | 6.42M | 5.37M | 5.92M | 2.89M | 7.15M |
| Total stockholder equity | 20.93M | 14.59M | -1.56M | 12.30M | -0.75M |
| Other current liab | 1.75M | 2.02M | 1.71M | 0.84M | 6.09M |
| Common stock | 0.06M | 0.04M | 0.01M | 0.00M | 0.00M |
| Capital stock | 0.34M | 0.32M | 0.01M | 0.01M | 0.01M |
| Retained earnings | -141.18M | -111.12M | -88.47M | -59.16M | -49.48M |
| Good will | 10.74M | 0.00M | - | - | - |
| Cash | 3.62M | 12.66M | 3.67M | 14.25M | 5.55M |
| Total current liabilities | 5.92M | 5.33M | 3.60M | 2.87M | 7.15M |
| Net debt | -2.92M | -12.45M | -1.32M | -14.11M | -4.90M |
| Short term debt | 0.40M | 0.16M | 0.02M | 0.12M | 0.64M |
| Short long term debt | 0.20M | - | - | - | 0.64M |
| Short long term debt total | 0.70M | 0.20M | 2.34M | 0.14M | 0.64M |
| Other stockholder equity | 161.78M | 125.40M | 86.90M | 71.45M | 48.72M |
| Total current assets | 4.62M | 19.61M | 4.16M | 14.74M | 5.68M |
| Net receivables | - | 0.22M | 0.33M | 0.10M | - |
| Long term debt | - | - | 2.32M | - | - |
| Inventory | - | 0.21M | - | - | - |
| Accounts payable | 3.77M | 3.15M | 1.87M | 1.92M | 0.41M |
| Non currrent assets other | 11.31M | 0.03M | - | 0.03M | 0.10M |
| Non current assets total | 22.73M | 0.36M | 0.20M | 0.45M | 0.72M |
| Capital lease obligations | 0.50M | 0.20M | 0.02M | 0.14M | 0.00M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Investments | - | -6.05M | -1.30M | -0.04M | -0.00M |
| Total cashflows from investing activities | -1.34M | -6.05M | -1.30M | -0.04M | -0.00M |
| Net borrowings | 0.62M | 28.57M | 2.69M | -0.35M | 0.29M |
| Total cash from financing activities | 19.93M | 29.77M | 2.66M | 16.25M | 7.04M |
| Net income | -30.05M | -21.68M | -29.32M | -9.37M | -7.02M |
| Change in cash | -9.04M | 8.99M | -10.59M | 8.71M | 0.48M |
| Begin period cash flow | 12.66M | 3.67M | 14.25M | 5.55M | 5.07M |
| End period cash flow | 3.62M | 12.66M | 3.67M | 14.25M | 5.55M |
| Total cash from operating activities | -27.63M | -14.73M | -11.95M | -7.51M | -6.56M |
| Issuance of capital stock | 18.30M | 5.00M | 0.00M | 16.60M | 6.75M |
| Depreciation | 0.07M | 0.12M | 0.18M | 0.37M | 0.38M |
| Dividends paid | 0.01M | 0.00M | 0.01M | 0.01M | 0.01M |
| Sale purchase of stock | - | 0.00M | -0.02M | 0.00M | - |
| Other cashflows from financing activities | -2.61M | -3.80M | 0.02M | 16.60M | 1.16M |
| Capital expenditures | 0.08M | 0.06M | 0.08M | 0.04M | 0.00M |
| Change in working capital | -3.15M | 3.29M | 0.49M | 1.56M | -0.06M |
| Stock based compensation | 6.42M | 1.96M | 0.48M | 0.22M | 0.65M |
| Other non cash items | -0.92M | 1.59M | 16.22M | -0.29M | -0.53M |
| Free cash flow | -27.71M | -14.79M | -12.03M | -7.54M | -6.57M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| HURA TuHURA Biosciences Inc |
0.04 2.42% |
1.70 | - | - | - | 7.19 |
| NVO Novo Nordisk A/S |
1.99 4.95% |
42.18 | 41.58 | 31.15 | 2.13 | 32.99 |
| VRTX Vertex Pharmaceuticals Inc |
18.28 3.44% |
549.04 | 30.22 | 24.27 | 10.36 | 6.50 |
| REGN Regeneron Pharmaceuticals Inc |
-41.91 4.31% |
931.45 | 29.07 | 20.12 | 7.57 | 3.82 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 |
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-functional and bi-specific antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.
10500 University Center Drive, Tampa, FL, United States, 33612
813 875 6600
22
| Name | Title | Year Born |
|---|---|---|
| Dr. James A. Bianco M.D. | President, CEO & Director | 1957 |
| Mr. Dan Dearborn CPA | Executive VP of Finance & CFO | 1967 |
| Mr. Michael Lawman | Co-Founder | NA |
| Ms. Patricia Lawman | Co-Founder | NA |
| Mr. Michael Krsulich | Head of Quality Assurance | NA |
| Ms. Amanda Garofalo | Senior Vice President of Clinical Operations | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+2.10%
Communication Services
+1.48%
Consumer Cyclical
+2.12%
Consumer Defensive
+1.59%
Energy
-2.52%
Financial Services
+1.11%
Financials
-6.05%
Healthcare
+2.12%
Industrials
-0.12%
Real Estate
+1.25%
Technology
-0.07%
Utilities
+0.57%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...